Avient Corporation vs Neurocrine Biosciences Inc — how do they compare? Avient Corporation trades at $45.35 (market cap $4.17B), while Neurocrine Biosciences Inc trades at $157.33 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.9× Avient Corporation's market cap, and Avient Corporation pays a 2.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AVNT | NBIX | |
|---|---|---|
Market Cap | $4.17B | $16.46B |
Sector | Technology | Health |
52-Week High | $45.69 | $185.50 |
52-Week Low | $27.48 | $123.10 |
Enterprise Value | $5.62B | $16.48B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →